Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in ankylosing spondylitis: extra-articular manifestations and long-term routine practice follow-up
NL-OMON39096Phase 4Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in ankylosing spondylitis (AS), sponsored by Merck & Co. Primary endpoint: Difference in uveitis incidence rate before and after golimumab. Started Nov 2012; status: active, not recruiting.
02
Drugs
golimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON39096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39096.